Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Weight loss becomes a beneficial side effect of necessary diabetes treatment
doi: 10.3920/bm2016.0207 108
MOTS-c A mitochondrial-derived peptide investigated for metabolic and energy-regulation questions that complement tri-agonist work
UK patients should understand that: Available evidence is largely from Phase 2 studies with relatively short follow-up periods Long-term cardiovascular outcome data are not yet available for either agent Phase 3 trials are ongoing, and results will inform future regulatory submissions to the MHRA UK patients interested in accessing these treatments through clinical trials may wish to consult the NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk) or ClinicalTrials.gov for current recruitment opportunities
US$ 27.00
US$ 27.05
US$ 28.63
US$ 21.75
US$ 26.76
US$ 22.17
US$ 22.25
US$ 23.11
